Compare CVS Health Corp (CVS) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Vanguard International High Dividend Yield ETF — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Vanguard International High Dividend Yield ETF trades at $101.99 (market cap $22.80B). The key difference: CVS Health Corp is far larger — about 4.9× Vanguard International High Dividend Yield ETF's market cap, and CVS Health Corp pays a 3.02% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| CVS | VYMI | |
|---|---|---|
Market Cap | $112.49B | $22.80B |
Volume | 8,467,392 | 1,300,061 |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $107.13 |
52-Week Low | $70.08 | $82.92 |
Typical Hold Time | 83 Days | 50 Days |
Enterprise Value | $174.83B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
VYMI trades at $100.23, down 1.11% with a bearish technical signal from moving averages. The ETF offers international diversification with a focus on high dividend yields, recently announcing a $0.82 dividend payment scheduled for September 2026. Recent institutional buying activity from firms like Envestnet and Corient Private Wealth indicates growing institutional interest despite the current technical weakness.
The outlook remains constructive given VYMI's strong historical performance (14.13% 5-year average annual return) and dividend growth potential. Key risks include global market volatility and currency fluctuations affecting international holdings. The ETF's financials-heavy portfolio (43.6% allocation) positions it to benefit from rising global interest rates, though this concentration also increases sector-specific risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
